NCT05023655 2026-03-17
Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation
Prisma Health-Upstate
Phase 2 Terminated
Clinical Trials
7 trialsNCT04705818 2026-03-06
CAIRE
Institut Bergonié
Phase 2 Completed
NCT04917042 2026-02-04
Tazemetostat in Malignant Peripheral Nerve Sheath Tumors
University of Florida
Phase 2 Active not recruiting
NCT06575686 2026-01-21
Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
City of Hope Medical Center
Phase 2 Suspended
NCT06242834 2026-01-14
Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
Northwestern University
Phase 2 Recruiting
NCT06692452 2026-01-07
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
Dana-Farber Cancer Institute
Phase 2 Suspended
NCT05994235 2025-04-09
Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma
Weill Medical College of Cornell University
Phase 2 Recruiting